Biogen shares rose sharply in pre-open trading, jumping +6.59% to $218 as investors reacted to topline results from the Phase 2 CELIA trial of diranersen (BIIB080). The company posted the CELIA topline data on Thursday, May 14, 2026, and characterized the results as "the first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease."
Diranersen is an antisense oligonucleotide developed to reduce production of tau protein by targeting microtubule-associated protein tau (MAPT) mRNA in the brain. Biogen said that despite the trial not meeting its primary dose-response endpoint, encouraging signals observed in the data support advancing the program into registrational development.
The CELIA announcement came on the heels of a solid first-quarter performance for Biogen. The company reported non-GAAP earnings per share of $3.57, ahead of the consensus estimate of $2.95, and revenue of $2.48 billion, surpassing the Street forecast of $2.29 billion. These financial results provided a proximate tailwind as the clinical readout landed.
Analysts reacted quickly to the CELIA news and the broader company update. Goldman Sachs raised its price target to $238 and retained a Buy rating. Guggenheim elevated its target to $260 while also maintaining a Buy. H.C. Wainwright reiterated a Buy rating with a $237 price target that the firm tied to the CELIA trial timeline. Separately, partner Ionis Pharmaceuticals confirmed Biogen’s decision to move diranersen forward, reinforcing confidence in the path toward registrational study.
Market conditions supported the equity move. The S&P 500 climbed +0.58% and the NASDAQ gained +1.20%, reflecting a risk-on tone that amplified the biotech-specific catalyst. The Dow Jones Industrial Average was slightly lower at -0.14%, indicating the gains were concentrated in technology and growth-oriented sectors where large-cap biotech stocks such as Biogen typically trade. There were no major Federal Reserve announcements or notable macro releases cited as drivers of the session.
The convergence of factors today - a novel tau-targeting clinical signal, a declared path to Phase 3 development, a recent earnings beat, and multiple bullish analyst revisions - created a compound catalyst for the stock. Biogen emphasized that the CELIA topline data provide both biological evidence of tau reduction and a clinical benefit signal in early Alzheimer’s patients, marking a notable milestone for this mechanism of action.
Key takeaways
- Celia Phase 2 topline readout prompted a pre-market jump of +6.59% in Biogen shares to $218.
- Despite missing the primary dose-response endpoint, Biogen will advance diranersen into registrational development based on encouraging signals.
- Q1 2026 earnings beat and multiple analyst price target increases added to the positive sentiment; market-wide risk-on tone helped amplify gains.
Risks and uncertainties
- The CELIA study did not meet its primary dose-response endpoint, a limitation explicitly acknowledged by the company and a source of uncertainty for the program.
- The announcement is based on topline data; full data release and peer review will be necessary to confirm the preliminary signals described.
- Today's gains were concentrated in growth and technology sectors, suggesting the move may be susceptible to sector rotation or broader market sentiment shifts.
Biogen's decision to proceed toward registrational development for diranersen, together with the firm's earnings outperformance and positive analyst follow-through, underpinned investor interest. The longer-term commercial and regulatory path will depend on confirmatory evidence from subsequent studies and the full set of trial data as it becomes available.